"Atlanta Diabetes Associates
Welcome,         Profile    Billing    Logout  
 11 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bode, Bruce
NCT04605991: A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Recruiting
3
167
US
LY900014, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes
02/22
02/22
NCT04628481: A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function

Recruiting
3
327
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A
New-onset type1 Diabetes
06/23
06/24
SURMOUNT-2, NCT04657003: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Recruiting
3
900
Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 2 Diabetes, Overweight, Obesity
06/23
07/23
SURPASS-CVOT, NCT04255433 / 2019-002735-28: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Checkmark [VIRTUAL] The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes
Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Dulaglutide, LY2189265
Eli Lilly and Company
Type 2 Diabetes Mellitus
10/24
10/24
NCT04899271 / 2020-002966-15: A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Recruiting
2
75
Europe, US, RoW
Ladarixin, LDX, Placebo
Dompé Farmaceutici S.p.A
New-onset Type 1 Diabetes
06/23
12/23
NCT04203823: Feasibility Studies of Personalized Closed Loop

Recruiting
N/A
200
US
Cloud-based Digital Twin and Meal Prediction algorithms
Medtronic Diabetes
Type 1 Diabetes
09/21
03/22
NCT04823312: Evaluation of Medtronic DUO Extended Set

Recruiting
N/A
20
US
Experimental prospective single arm evaluating the Medtronic Duo Extended Set, Medtronic DUO Extended Set with 670G Pump Therapy
Atlanta Diabetes Associates, Medtronic
Diabetes Mellitus, Type 1
10/21
11/21
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices

Recruiting
N/A
500
US
Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app
Medtronic Diabetes
Type 1 Diabetes Mellitus
04/22
04/22
NCT02748018: Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

Recruiting
N/A
280
Europe, Canada, US
670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
Medtronic Diabetes
Type 1 Diabetes
07/22
01/23
NCT03908125: Post Approval Study of the Eversense® Continuous Glucose Monitoring

Recruiting
N/A
400
US
Eversense® CGM system
Senseonics, Inc.
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
03/23
03/23
NA-PAS, NCT04836546: Eversense® Non-adjunctive Use Post Approval Study

Recruiting
N/A
925
US
Blood glucose meter, Eversense CGM System
Senseonics, Inc.
Diabetes
03/26
03/26

Download Options